Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy

The anti-CD20-specific monoclonal antibody rituximab (RTX), in combination with chemotherapy, is commonly used for primary treatment in chronic lymphocytic leukemia (CLL). However, relapses remain important and activation of the complement pathway is one of the mechanisms by which RTX generates the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bordron, Anne, Bagacean, Cristina, Mohr, Audrey, Tempescul, Adrian, Bendaoud, Boutahar, Deshayes, Stéphanie, Dalbies, Florence, Buors, Caroline, Saad, Hussam, Berthou, Christian, Pers, Jacques-Olivier, Renaudineau, Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114972/
https://www.ncbi.nlm.nih.gov/pubmed/30167081
http://dx.doi.org/10.18632/oncotarget.25657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114972/
https://www.ncbi.nlm.nih.gov/pubmed/30167081
http://dx.doi.org/10.18632/oncotarget.25657

Ejemplares similares